UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $4 Million Stock Holdings in Sarepta Therapeutics, Inc. $SRPT

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 19.7% during the 2nd quarter, HoldingsChannel reports. The fund owned 222,496 shares of the biotechnology company’s stock after selling 54,459 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Sarepta Therapeutics were worth $3,998,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Kestra Advisory Services LLC bought a new stake in shares of Sarepta Therapeutics in the 4th quarter worth approximately $25,000. iSAM Funds UK Ltd acquired a new position in shares of Sarepta Therapeutics in the third quarter valued at $25,000. Ancora Advisors LLC raised its stake in shares of Sarepta Therapeutics by 200.0% in the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Sarepta Therapeutics in the second quarter worth $27,000. Finally, Allworth Financial LP lifted its position in Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,721 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $22.02 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62. The stock has a fifty day moving average price of $18.50 and a two-hundred day moving average price of $18.55. Sarepta Therapeutics, Inc. has a 52-week low of $14.68 and a 52-week high of $25.32. The firm has a market capitalization of $2.33 billion, a P/E ratio of -7.59, a P/E/G ratio of 0.30 and a beta of 0.27.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The company had revenue of $401.25 million for the quarter, compared to the consensus estimate of $366.39 million. During the same quarter in the previous year, the company earned $2.02 EPS. The firm’s revenue for the quarter was down 34.3% compared to the same quarter last year. As a group, analysts anticipate that Sarepta Therapeutics, Inc. will post 3.52 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on SRPT. Zacks Research raised shares of Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Wall Street Zen downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings upgraded shares of Sarepta Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. Benchmark reissued a “sell” rating on shares of Sarepta Therapeutics in a research note on Wednesday. Finally, Wolfe Research raised shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target for the company in a research report on Thursday, July 9th. Nine equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and six have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $25.69.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.